Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone

Rascol O., Barone P., Behari M., Emre M., Giladi N., Olanow C. W., ...More

CLINICAL NEUROPHARMACOLOGY, vol.35, no.1, pp.15-20, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 35 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.1097/wnf.0b013e318241520b
  • Journal Name: CLINICAL NEUROPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.15-20
  • Istanbul University Affiliated: Yes

Abstract

Objectives: Perampanel is a selective and noncompetitive alpha-amino-3-hydroxy-5-methylisoxazole propionic acid-type glutamate receptor antagonist that improves motor symptoms in animal models of Parkinson disease (PD). The aim of this study was to assess the efficacy and tolerability of perampanel in L-dopa-treated patients with moderately severe PD and motor fluctuations using an active comparator study design.